These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 34720102)
1. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Quhal F; Mori K; Fajkovic H; Remzi M; Shariat SF; Schmidinger M Curr Opin Urol; 2022 Jan; 32(1):61-68. PubMed ID: 34720102 [TBL] [Abstract][Full Text] [Related]
2. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737 [TBL] [Abstract][Full Text] [Related]
3. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559 [TBL] [Abstract][Full Text] [Related]
4. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. Yanagisawa T; Kawada T; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Chlosta M; Quhal F; Pradere B; Karakiewicz PI; Mori K; Kimura T; Shariat SF; Schmidinger M BJU Int; 2024 Sep; 134(3):323-336. PubMed ID: 38659099 [TBL] [Abstract][Full Text] [Related]
5. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Yanagisawa T; Mori K; Matsukawa A; Kawada T; Katayama S; Bekku K; Laukhtina E; Rajwa P; Quhal F; Pradere B; Fukuokaya W; Iwatani K; Murakami M; Bensalah K; Grünwald V; Schmidinger M; Shariat SF; Kimura T Cancer Immunol Immunother; 2024 Jan; 73(2):38. PubMed ID: 38289361 [TBL] [Abstract][Full Text] [Related]
6. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis. Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X Front Immunol; 2024; 15():1255577. PubMed ID: 38390328 [TBL] [Abstract][Full Text] [Related]
8. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851 [TBL] [Abstract][Full Text] [Related]
9. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab. Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206 [No Abstract] [Full Text] [Related]
12. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis. Fujiwara Y; Miyashita H; Liaw BC Cancer Immunol Immunother; 2023 Jun; 72(6):1355-1364. PubMed ID: 36495342 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572 [TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Santoni M; Rizzo A; Mollica V; Rosellini M; Marchetti A; Fragomeno B; Battelli N; Massari F Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):45-51. PubMed ID: 34058953 [TBL] [Abstract][Full Text] [Related]
16. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659 [TBL] [Abstract][Full Text] [Related]
17. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Lombardi P; Filetti M; Falcone R; Di Bidino R; Iacovelli R; Ciccarese C; Bria E; Tortora G; Scambia G; Daniele G Cancer Treat Rev; 2022 May; 106():102377. PubMed ID: 35313232 [TBL] [Abstract][Full Text] [Related]
18. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611 [TBL] [Abstract][Full Text] [Related]
19. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Buti S; Bersanelli M; Mazzaschi G; Cattrini C; Brunelli M; Di Maio M Immunotherapy; 2022 Feb; 14(2):145-153. PubMed ID: 34806404 [No Abstract] [Full Text] [Related]
20. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. Watson TR; Gao X; Reynolds KL; Kong CY JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]